Transglutaminase inhibitors and methods of use thereof

Details Transglutaminase inhibitors and methods of use thereof Transglutaminase inhibitors and methods of use thereof

2005-08-26

2009-08-25

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S001690, C514S016700, C514S017400

Reexamination Certificate

active

07579313

ABSTRACT:
Transglutaminase inhibitors and methods of use thereof are provided.

REFERENCES:
patent: 4203967 (1980-05-01), Gallo-Torres
patent: 4912120 (1990-03-01), Castelhano et al.
patent: 4929630 (1990-05-01), Castelhano et al.
patent: 5208021 (1993-05-01), Johnson et al.
patent: 5817523 (1998-10-01), Picarelli
patent: 5834428 (1998-11-01), Drucker
patent: 6197356 (2001-03-01), Girsh
patent: 6319726 (2001-11-01), Schuppan et al.
patent: 6410550 (2002-06-01), Coe et al.
patent: 2001/0007690 (2001-07-01), Girsh
patent: 2001/0036639 (2001-11-01), Fine
patent: 2002/0039599 (2002-04-01), Lin et al.
patent: 2002/0076834 (2002-06-01), Detlef et al.
patent: 2003/0215438 (2003-11-01), Hausch et al.
patent: 2003/0224476 (2003-12-01), Chou
patent: 2004/0167069 (2004-08-01), Khosla et al.
patent: 2004/0241664 (2004-12-01), Dekker et al.
patent: 2005/0090653 (2005-04-01), Klaveness et al.
patent: 0 237 082 (1987-09-01), None
patent: 0 905 518 (1999-03-01), None
patent: WO 94/26774 (1994-11-01), None
patent: WO 01/25793 (2001-04-01), None
patent: WO 03/068170 (2003-08-01), None
Arentz-Hansen et al. “Celiac Lesion T Cells Recognizes Epitopes that Cluster in Regions of Gliadins Rich in Proline Residues” Gastroenterology, 2002, pp. 803-809, vol. 123, No. 3.
Colot et al. “The Genes Encoding Wheat Storage Proteins: Towards A Molecular Understanding Of Bread-Making Quality And Its Genetic Manipulation” Genet Eng, 1990, pp. 225-241, vol. 12.
de Ritis G. et al. “In Vitro (organ culture) Studies of the Toxicity of Specific A-Gliadin Peptides in celiac Disease” Gastroenbterology, 1988, pp. 41-49, vol. 94.
Frazer et al. “Gluten-induced enteropathy: the effect of partially digested gluten.” Lancet, Sep. 5, 1959, pp. 252-255, vol. 2.
Fruend, K. et al. “Transglutaminase inhibition by 2-[(2-Oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation” Biochemistry, 1994, pp. 10109-10119, vol. 33.
Kao Castle Pty LTD Sequence Analysis PCTRIS03104743.
Lion.Flavobacterium meningosepticum. Genbank Accession #/EMBL #: D10980. Aug. 1, 1992. http://www.infobiogen.fr/srs71bin/cgi-bin/wgetz?-id+4jqa61Mc9PO+[uniprot-ID:PPCE—FLAME]+-e.
Messer et al. “Studies On The Mechanism Of Destruction Of The Toxic Action Of Wheat Gluten In Coeliac Disease By Crude Papain” Gut., Aug. 1964, pp. 295-303, vol. 5.
Messer et al.“Oral papain in gluten intolerance.” Lancet, Nov. 6, 1976, p. 1022, vol. 2, Issue 7993.
Moodie, P. “Traditional Baking Enzymes-Proteases” Presented at the American Institute of Baking, Manhattan, Kansas, May 7, 2001 by Peter Moodie, Director—Sales & Marketing, Enzyme Development Corporation, Enzyme Development Corporation.
Online-Medical Dictionary. “Amino acid”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid. Nov. 13, 1997.
Piper et al., “High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac spure”, Biochemistry, Jan. 8, 2002, pp. 386-393, vol. 41, Issue 1.
Piper, J., et al., “Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo,” The Journal of Pharmacology and Experimental Therapeutics, 2004, pp. 213-219, vol. 311, Issue 1.
Shan, L. et al. “Structural Basis for Gluten Intolerance in Celiac Sprue” Science 2002, pp. 2275-2279, vol. 297.
Shan, L. et al. “Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications of coeliac sprue,” Biochem J, 2004, pp. 311-318, vol. 383.
Sjostrom et al. “Identification of a Gliadin T-Cell Epitope in Coeliac Disease: General Importance of Gliadin Deamidation for Intestinal T-Cell Recognition” Scandinavian Journal of Immunology, Aug. 1998, pp. 111-115(5), vol. 48, No. 2.
Stepniak, D. et al. “Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease,”Am J Physiol Gastrointest Liver Physiol, 2006, pp. G621-G629, vol. 291.
Vader et al. “The Gluten Response in Children with Celiac Sprue Disease is Directed Toward Multiple Gliadin and Glutenin Peptides” Gastroenterology, 2002, pp. 1729-1737, vol. 122.
Vader et al. “The HLA-DQ2 Gene Dose Effect in Celiac Disease is Doirectly Related to the Magnitude and Breadth of Gluten-Specific T Cell Responses” PNAS, Oct. 14, 2003, pp. 12390-12395, vol. 123, No. 3.
Wieser “The Precipitating Factor In Coeliac Disease” Baillieres Clinical Gastroenterol, 1995, pp. 191-207, vol. 9, Issue 2.
Database Derwent, Acc-No. 1996-329479.
Ahnen et al., Intestinal Aminooligopeptidase in Vivo Synthesis on Intracellualar Membranes of Rat Jejunum, J. Biol. Chem., (1982), 257: 12129-35.
Arentz-Hansen et al., The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease is Focused on a Single Deamidated Glutamine Targeted by Tissue Transglutaminase, J. Exp. Med., (2000), 191: 603-12.
Bordusa et al., The Specificity of Prolyl Endopeptidase FromFlavobacterium meningoseptum: Mapping the S' Subsites by Positional Scanning via Acyl Transfer, Bioorg. Med. Chem., (1998), 6: 1775-80.
Greenberg, C., et al., “Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues,” (1991)FASEB J., 5:3071-3077.
Hitomi, K., et al., “GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3),” (2000)Biosci. Biotechnol. Biochem., 64(3):657-659.
Lahteenoja et al., Local Challenge on Oral Mucosa with an α-Gliadin Related Synthetic Peptide in Patients With Celiac Disease, Am. J. Gastroenterol., (2000), 95: 2880.
Sárdy, M., et al., “Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis,”(2002)J. Exp. Med., 195(6):747-757.
Schuppan, Detlef, Special Reports and Reviews Current Concepts of Celiac Disease Pathogenesis, Gastroenterology, (2000), 119: 234-42.
Wieser, Herbert, The Precipitating Factor in Coeliac Disease, Baillieres Clin Gastroenterol, (1995) , 9(2):191-207.
Yoshimoto et al., Prolyl Endopeptidase FromFlavobacterium meningosepticum: Cloning and Sequencing of the Enzyme Gene, J. Biochem., (1991), 110: 873-8.
Castelhano et al., Synthesis, Chemistry, and Absolute Configuratin of Novel Transglutaminiase Inhibitors Containing a 3-Halo-4,5-dihydroisoxazole1, Bioorg. Chem. 1988 16: 335-340.
Choi et al., Chemistry and Biology of Dihydroisoxazole Derivatives: Selectives Inhibitors of Human Transglutaminase 2, Chem. & Biol., 2005, 12: 469-475.
Hausch et al., Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase, Chem Biol. Mar. 2003;10(3):225-31.
Karpuj et al., Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine, Nat Med. Feb. 2002;8(2):143-9.
Keillor, Jeffrey W., Tissue Transglutaminase Inhibition, Chem. & Biol., 2005, 12: 410-412.
Kim et al., Transglutaminases in disease, Neurochem. Int., 2002, 40:85-103.
Lorand et al., Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins, Exp Eye Res. May 1998;66 :531-6.
Martinet et al., In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer, Am J Respir Cell Mol Biol. Apr. 2003;28(4):428-35.
Zhang et al., Identification of differentially expressed proteins in human glioblastoma cell lines and tumors, Glia. Apr. 15, 2003;42(2):194-208.

Affiliated with

Also associated with

Rating

Transglutaminase inhibitors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transglutaminase inhibitors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transglutaminase inhibitors and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4117422